iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/32247927
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May-Jun:35:101647.
doi: 10.1016/j.tmaid.2020.101647. Epub 2020 Apr 2.

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Yu-Chen Cao  1 , Qi-Xin Deng  1 , Shi-Xue Dai  2
Affiliations
Review

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Yu-Chen Cao et al. Travel Med Infect Dis. 2020 May-Jun.

Abstract

The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.

Keywords: Corona virus disease 2019; Phase III clinical trial; Remdesivir; Severe acute respiratory syndrome coronavirus 2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors report no conflicts.

Figures

Fig. 1
Fig. 1
The RNA diagram of SARS-CoV-2 The structure of spike protein is downloaded from RCSB PBD (http://www.rcsb.org/pdb/home/home.do, accessed Feb 25); The model that S protein receptor binding domain (RBD) bind to ACE2 is downloaded from National Microbiology Data Center (http://nmdc.cn/?from=groupmessage&isappinstalled=0#/, accessed Feb 25).
Fig. 2
Fig. 2
SARS-CoV-2 invasion process and how remdesivir works 1 SARS-CoV-2 enters target cells by binding the S protein to the ACE2 receptor on the cell surface; 2 Remdeivir, the nucleotide analogues, act as RdRp inhibitors, can provide a scheme for blocking RNA replication; 3Once remdesivir added into the growing chain (i position), is cannot cause an immediate stop. On the contrary, it will continue to extend three more nucleotides down to stop the strand at (i + 3) position; 4 Remdesivir triphosphate cannot be removed by nsp14-ExoN.
Fig. 3
Fig. 3
Structure of remdesivir and its precursors and metabolites The original structure of the drug is derived from DRUGBANK (https://www.drugbank.ca, accessed Feb 25).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Liu W., Morse J.S., Lalonde T. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738. - PMC - PubMed
    1. W M., C R., Z L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. - PMC - PubMed
    1. L H., W Ym, X Jy. [Potential antiviral therapeutics for 2019 novel coronavirus]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tubercul Respir Dis. 2020;43:E2. - PubMed
    1. Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. - PMC - PubMed
    1. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. - PMC - PubMed

MeSH terms